Astrana Health, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Astrana Health reported Q2 2026 revenue of $972.5M (up 49% YoY) and net income of $19.7M (up 109% YoY); adjusted EBITDA of $68.9M (up 43% YoY). For full-year 2026, the company raised adjusted EBITDA guidance to $255–$280M (from prior range), while reaffirming revenue guidance of $3.8–$4.1B and free cash flow guidance of $105–$132.5M. The company serves ~1.5M patients through ~20,000 providers; 81% of capitation revenue is now from full-risk arrangements. YTD operating cash flow was $100.8M with free cash flow of $92.9M.
Why this rating
Strong beat on earnings and guidance raise (7% of market cap in full-year EBITDA range) demonstrates solid execution; material cash generation and risk progression support trajectory. Meaningful but not transformational relative to $1.1B market cap.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.